Catapano , A L , Graham , I , De Backer , G , Wiklund , O , Chapman , M J , Drexel , H , Hoes , A W , Jennings , C S , Landmesser , U , Pedersen , T R , Reiner , Z , Riccardi , G , Taskinen , M-R , Tokgozoglu , L , Verschuren , W M M , Vlachopoulos , C , Wood , D A & Luis Zamorano , J 2016 , ' 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR) ' , Atherosclerosis , vol. 253 , pp. 281-344 . https://doi.org/10.1016/j.atherosclerosis.2016.08.018
Title: | 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR) |
Author: | Catapano, Alberico L.; Graham, Ian; De Backer, Guy; Wiklund, Olov; Chapman, M. John; Drexel, Heinz; Hoes, Arno W.; Jennings, Catriona S.; Landmesser, Ulf; Pedersen, Terje R.; Reiner, Zeljko; Riccardi, Gabriele; Taskinen, Marja-Riita; Tokgozoglu, Lale; Verschuren, W. M. Monique; Vlachopoulos, Charalambos; Wood, David A.; Luis Zamorano, Jose |
Contributor organization: | Research Programs Unit Marja-Riitta Taskinen Research Group Department of Medicine Diabetes and Obesity Research Program Clinicum |
Date: | 2016-10 |
Language: | eng |
Number of pages: | 64 |
Belongs to series: | Atherosclerosis |
ISSN: | 0021-9150 |
DOI: | https://doi.org/10.1016/j.atherosclerosis.2016.08.018 |
URI: | http://hdl.handle.net/10138/232152 |
Subject: |
dyslipidaemias
cholesterol triglycerides low-density lipoproteins high-density lipoproteins apolipoprotein B lipoprotein remnants total cardiovascular risk treatment, lifestyle treatment, drugs treatment, adherence CORONARY-HEART-DISEASE DENSITY-LIPOPROTEIN CHOLESTEROL RANDOMIZED CONTROLLED-TRIALS HIGH-DOSE ATORVASTATIN TYPE-2 DIABETES-MELLITUS LIPID-LOWERING THERAPY CHRONIC KIDNEY-DISEASE POPULATION-BASED COHORT APOLIPOPROTEIN C-III ALL-CAUSE MORTALITY 3121 General medicine, internal medicine and other clinical medicine |
Peer reviewed: | Yes |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
1_s2.0_S0021915016312679_main.pdf | 11.86Mb |
View/ |